Enhancing the healing power of plants
Floratek is a privately owned, Swiss-based pharmaceutical company focused on discovering and advancing novel therapeutics for safe and effective treatment of diseases in the fields of cancer and central nervous system (CNS) disorders.
Leveraging artificial intelligence and advanced computational modeling, Floratek accelerates drug discovery, optimizing compounds for targeted biological activities and early-stage clinical development.
Floratek's pipeline of novel small-molecule drugs leverages the plant kingdom's abundant and potent source of polyphenols, chemically optimized to influence critical biological processes. These carefully engineered molecules modulate complex cellular signaling pathways implicated in selective cytotoxicity, neuroprotection, immunomodulation, and anti-aging.
Floratek's pipeline of novel small-molecule drugs leverages the plant kingdom's abundant and potent source of polyphenols, chemically optimized to influence critical biological processes. These carefully engineered molecules modulate complex cellular signaling pathways implicated in selective cytotoxicity, neuroprotection, immunomodulation, and anti-aging.
Our research primarily targets metabolic differences between healthy and cancerous cells, particularly focusing on mitochondrial modulation. Utilizing cutting-edge artificial intelligence algorithms for structure-based drug design and predictive modeling, we've successfully developed and synthesized over 500 novel chemical entities derived from plant-based frameworks, thoroughly characterized for efficacy and specificity.
Currently, a dozen compounds exhibiting highly potent activity in vitro are undergoing extensive in vivo evaluation, with encouraging preliminary results underscoring their clinical potential.